| Roger Ramos, MD | |
|
5301 S Congress Ave, Atlantis, FL 33462-1149 | |
| (561) 548-3727 | |
| (561) 548-1238 |
| Full Name | Roger Ramos |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 38 Years |
| Location | 5301 S Congress Ave, Atlantis, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942276506 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | ME77450 (Florida) | Primary |
| 2085R0203X | Radiology - Therapeutic Radiology | ME77450 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elite Imaging Llc | 2466496880 | 108 |
News Archive
Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer.
Clinical and Laboratory Standards Institute recently published "Selection Criteria for Point-of-Care Testing Devices; Approved Guideline". This document provides guidance on selection of point-of-care testing devices based on the patient care setting and clinical needs.
A new drug candidate has been discovered by the University of South Australia to treat the most lethal form of brain cancer - glioblastoma - which kills 95 per cent of patients within five years.
In just over a month following the FDA's October 2010 approval of Roche's Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare.
A more efficient and much faster method to assess high levels of neutralizing antibodies to COVID-19 could point the way to better understanding and treatment of the disease, according to new published findings by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) and the University of Michigan (U-M).
› Verified 9 days ago
| Entity Name | Elite Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346516853 PECOS PAC ID: 2466496880 Enrollment ID: O20050616000704 |
News Archive
Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer.
Clinical and Laboratory Standards Institute recently published "Selection Criteria for Point-of-Care Testing Devices; Approved Guideline". This document provides guidance on selection of point-of-care testing devices based on the patient care setting and clinical needs.
A new drug candidate has been discovered by the University of South Australia to treat the most lethal form of brain cancer - glioblastoma - which kills 95 per cent of patients within five years.
In just over a month following the FDA's October 2010 approval of Roche's Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare.
A more efficient and much faster method to assess high levels of neutralizing antibodies to COVID-19 could point the way to better understanding and treatment of the disease, according to new published findings by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) and the University of Michigan (U-M).
› Verified 9 days ago
| Entity Name | Independent Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013908912 PECOS PAC ID: 4587694716 Enrollment ID: O20050817000898 |
News Archive
Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer.
Clinical and Laboratory Standards Institute recently published "Selection Criteria for Point-of-Care Testing Devices; Approved Guideline". This document provides guidance on selection of point-of-care testing devices based on the patient care setting and clinical needs.
A new drug candidate has been discovered by the University of South Australia to treat the most lethal form of brain cancer - glioblastoma - which kills 95 per cent of patients within five years.
In just over a month following the FDA's October 2010 approval of Roche's Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare.
A more efficient and much faster method to assess high levels of neutralizing antibodies to COVID-19 could point the way to better understanding and treatment of the disease, according to new published findings by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) and the University of Michigan (U-M).
› Verified 9 days ago
| Entity Name | Blue Radiology Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174976468 PECOS PAC ID: 9032407382 Enrollment ID: O20161019001652 |
News Archive
Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer.
Clinical and Laboratory Standards Institute recently published "Selection Criteria for Point-of-Care Testing Devices; Approved Guideline". This document provides guidance on selection of point-of-care testing devices based on the patient care setting and clinical needs.
A new drug candidate has been discovered by the University of South Australia to treat the most lethal form of brain cancer - glioblastoma - which kills 95 per cent of patients within five years.
In just over a month following the FDA's October 2010 approval of Roche's Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare.
A more efficient and much faster method to assess high levels of neutralizing antibodies to COVID-19 could point the way to better understanding and treatment of the disease, according to new published findings by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) and the University of Michigan (U-M).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Roger Ramos, MD Po Box 25164, Miami, FL 33102-5164 Ph: (305) 503-6320 | Roger Ramos, MD 5301 S Congress Ave, Atlantis, FL 33462-1149 Ph: (561) 548-3727 |
News Archive
Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer.
Clinical and Laboratory Standards Institute recently published "Selection Criteria for Point-of-Care Testing Devices; Approved Guideline". This document provides guidance on selection of point-of-care testing devices based on the patient care setting and clinical needs.
A new drug candidate has been discovered by the University of South Australia to treat the most lethal form of brain cancer - glioblastoma - which kills 95 per cent of patients within five years.
In just over a month following the FDA's October 2010 approval of Roche's Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare.
A more efficient and much faster method to assess high levels of neutralizing antibodies to COVID-19 could point the way to better understanding and treatment of the disease, according to new published findings by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) and the University of Michigan (U-M).
› Verified 9 days ago
Michael J Cohen, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 | |
Noa Ann Beck, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 | |
Mehdi Bathaii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 Fax: 561-548-1238 | |
Dr. Matthew Phillip Brill, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-601-9191 | |
Marat Bakman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 Fax: 561-548-1238 | |
David Mizrachi, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Palm Beach Radiology Professionals, Atlantis, FL 33462 Phone: 561-548-1230 Fax: 561-548-1283 | |
Steven Martin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 Fax: 561-548-1238 |